CNS Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CNSP Nasdaq 2834 cnspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth - Sep 1st, 2026 7:01 am
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference - Aug 27th, 2026 7:01 am
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - Aug 12th, 2026 6:00 am
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - Jun 8th, 2026 7:15 am
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress - May 20th, 2026 7:02 am
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6 - May 14th, 2026 9:39 am
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress - May 14th, 2026 6:00 am
Top Midday Gainers - May 4th, 2026 11:59 am
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing - May 4th, 2026 5:00 am
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline - Mar 11th, 2026 6:35 am
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Feb 17th, 2026 6:25 am
CNS Pharmaceuticals Issues Letter to Shareholders - Jan 27th, 2026 7:00 am
CNS Pharmaceuticals Announces CEO Transition - Dec 17th, 2025 5:00 am
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 17th, 2025 6:35 am
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting - Nov 10th, 2025 6:45 am